Clinically, elevated MMP-9 levels, whether in tumor tissue or circulation, correlate with poor prognosis, increased metastatic potential, and therapeutic resistance across malignancies including breast, colorectal, lung, and prostate cancers [37]. Here, MMP9 is linked to prostate carcinoma.